$5.76
+0.14(2.58%)
Mkt Cap $554M
$2.35
$8.45
52-Week Range
At a Glance
AI-generatedCOMPASS Pathways plc (CMPS), a clinical-stage biotech focused on mental health treatments, reported a net loss of $287.9 million for FY 2025, up from $155.1 million in FY 2024, driven by a $122.6 million non-cash fair value loss on warrant liabilities from the January 2025 financing.
8-K
COMPASS Pathways plc reported fourth quarter and full-year 2025 financial results, including a Q4 net loss of $93.9 million ($1.00 per share) and full-year net loss of $287.9 million ($3.08 per share), driven by non-cash warrant liability adjustments. The company announced plans for an FDA meeting to confirm NDA submission strategy for COMP360 in TRD by Q4 2026 and initiation of a Phase 2b/3 PTSD trial.$554M
Market Cap
—
Revenue
-$239M
Net Income
Employees166
Fundamentals
How The Business Makes Money
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Industry Medical - Care Facilities
Activity
What Changed Recently
Company Profile
CIK0001816590
ISINUS20451W1018
CUSIP20451W101
Phone44 64 6905 3974
Address33 Broadwick Street, London, W1F 0DQ, GB
SEC EDGAR